The relationship between symptoms and monoamine oxidase-B densities in the brain of depression and organic depression: A PET study with [11C]SL25.1188

The relationship between symptoms and monoamine oxidase-B densities in the brain of depression and organic depression: A PET study with [11C]SL25.1188 - The relationship between symptoms and monoamine oxidase-B densities in the brain of depression and organic depression: A PET study with [11C]SL25.1188

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045815

Enrollment

Registered

2021-10-21

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder, Organic depression

Interventions

PET with [11C]SL25.1188 and neuropsychological tests PET with [11C]SL25.1188 and neuropsychological tests PET with [11C]SL25.1188 and neuropsychological tests

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: I. Patients 20 y.o.<=Age patients with major depressive disorders (DSM-5), bipolar disorders (DSM-5) and organic depression (ICD-10) II. Healthy volunteers 20 y.o.<=Age normal subjects

Exclusion criteria

Exclusion criteria: I. Patients 1. Subjects undergoing dialysis 2. Subjects with a severe physical complication 3. Subjects with metallic medical device in the body 4. Subjects with severe claustrophobia 5. Subjects who tends to suicide 6. Pregnant women 7. Subjects participating in other clinical trials 8. Subjects who donated blood within 3 months 9. Subjects with allergy to local anesthetics and anticoagulants 10. Subjects taking anticoagulants 11. Subjects taking MAO inhibitors 12. Subjects taking supplements or health foods containing curcumin 13. Subjects taking foods, supplements, or health foods 10 hours before blood sampling 14. Subjects who is considered to be inappropriate to participate in the study II. Healthy volunteers 1. Subjects with any psychiatric disorder 2. Subjects with any organic brain disorder 3. Subjects with substance-related disorders 4. Subjects undergoing dialysis 5. Subjects with a severe physical complication 6. Subjects with metallic medical device in the body 7. Subjects with severe claustrophobia 8. Pregnant women 9. Subjects participating in other clinical trials 10. Subjects who donated blood within 3 months 11. Subjects with allergy to local anesthetics and anticoagulants 12. Subjects taking anticoagulants 13. Subjects taking MAO inhibitors 14. Subjects taking supplements or health foods containing curcumin 15. Subjects taking foods, supplements, or health foods 10 hours before blood sampling 16. Subjects who is considered to be inappropriate to participate in the study

Design outcomes

Primary

Measure	Time frame
Monoamine oxidase B (MAO-B) distribution volume of patients with major depressive disorders, bipolar disorders, organic depression and healthy subjects.	—

Countries

Japan

Contacts

Public ContactKeisuke Takahata

Institute for Quantum Medical Science Department of Functional Brain Imaging Research

takahata.keisuke@qst.go.jp0432063251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026